Pagonabarraga, J, Perez-Gonzalez, R, Bejr-kasem, H, Marin-Lahoz, J, Horta-Barba, A, Martinez-Horta, S, Aracil-Bolanos, I, Sampedro, F, Campolongo, A, Rivas, E, Puig-Davi, A, Ruiz-Barrios, I, Perez-Perez, J, Pascual-Sedano, B, Kulisevsky, J. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease. PARKINSONISM & RELATED DISORDERS. 2022; 105DOI:10.1016/j.parkreldis.2022.05.020. PMID:35752549. IF:4.100(Q2/3D).

Devos, D, Labreuche, J, Rascol, O, Corvol, JC, Duhamel, A, Delannoy, PG, Poewe, W, Compta, Y, Pavese, N, Ruzicka, E, Dusek, P, Post, B, Bloem, BR, Berg, D, Maetzler, W, Otto, M, Habert, MO, Lehericy, S, Ferreira, J, Dodel, R, Tranchant, C, Eusebio, A, Thobois, S, Marques, AR, Meissner, WG, Ory-Magne, F, Walter, U, de Bie, RMA, Gago, M, Vilas, D, Kulisevsky, J, Januario, C, Coelho, MVS, Behnke, S, Worth, P, Seppi, K, Ouk, T, Potey, C, Leclercq, C, Viard, R, Kuchcinski, G, Lopes, R, Pruvo, JP, Pigny, P, Garcon, G, Simonin, O, Carpentier, J, Rolland, AS, Nyholm, D, Scherfler, C, Mangin, JF, Chupin, M, Bordet, R, Dexter, DT, Fradette, C, Spino, M, Tricta, F, Ayton, S, Bush, AI, Devedjian, JC, Duce, JA, Cabantchik, I, Defebvre, L, Deplanque, D, Moreau, C. Trial of Deferiprone in Parkinson's Disease. NEW ENGLAND JOURNAL OF MEDICINE. 2022; 387(22)DOI:10.1056/NEJMoa2209254. PMID:36449420. IF:158.500(Q1/1D).

Pérez-López C., Hernández-Vara J., Caballol N., Bayes À., Buongiorno M., Lopez-Ariztegui N., Gironell A., López-Sánchez J., Martínez-Castrillo J.C., Sauco M A., López-Manzanares L., Escalante-Arroyo S., Pérez-Martínez D.A., Rodríguez-Molinero A.. Comparison of the Results of a Parkinson's Holter Monitor With Patient Diaries, in Real Conditions of Use: A Sub-analysis of the MoMoPa-EC Clinical Trial. Frontiers in Neurology. 2022; 13DOI:10.3389/fneur.2022.835249. PMID:35651347. IF:3.400(Q2/5D).

Bach-Morrow L., Boccalatte F., DeRosa A., Devos D., Garcia-Sanchez C., Inglese M., Droby A.. Functional changes in prefrontal cortex following frequency-specific training. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-24088-7. PMID:36434008. IF:4.600(Q2/4D).

Pou M.A., Orfila F., Pagonabarraga J., Ferrer-Moret S., Corominas H., Diaz-Torne C.. Le risque de maladie de Parkinson dans une population méditerranéenne de patients goutteux : étude cas-témoins. Revue Du Rhumatisme (edition Francaise). 2022; 89(6)DOI:10.1016/j.rhum.2022.09.019. PMID:. IF:(Q/D).

Kulisevsky J.. Pharmacological management of Parkinson's disease motor symptoms: update and recommendations from an expert. REVISTA DE NEUROLOGIA. 2022; 75(s04)DOI:10.33588/rn.75s04.2022217. PMID:36342310. IF:1.200(Q4/10D).

Rodríguez-Jorge F., Beltrán-Corbellini Á., Chico-García J.L., Parra-Díaz P., Baena-Álvarez B., Pagonabarraga J., Pérez-Torre P., Pareés I., López-Sendón J.L., Martínez-Castrillo J.C., Alonso-Cánovas A.. Efficacy and safety of high doses of safinamide in advanced Parkinson disease. PARKINSONISM & RELATED DISORDERS. 2022; 97DOI:10.1016/j.parkreldis.2022.03.010. PMID:35344893. IF:(Q/D).

Gonzalez-Herrero, B, Coebergh, J, Pagonabarraga, J, Morgante, F, Deeley, Q, Edwards, MJ. Structured clinical diagnostic assessment reveals autism spectrum disorder in adults with functional neurological disorder. Scientific Reports. 2025; 15(1)DOI:10.1038/s41598-025-20508-6. PMID:41253885. IF:3.900(Q1/2D).